Codexis, Inc. (CDXS)

Market Cap	252.68M
Revenue (ttm)	49.82M
Net Income (ttm)	-74.46M
Shares Out	82.84M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,608,390
Open	2.910
Previous Close	2.860
Day's Range	2.864 - 3.135
52-Week Range	1.900 - 6.080
Beta	2.55
Analysts	Buy
Price Target	11.00 (+260.66%)
Earnings Date	Aug 13, 2025

About CDXS

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorp...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 22, 2010
• Employees: 188
• Stock Exchange: NASDAQ
• Ticker Symbol: CDXS
• Website: https://www.codexis.com

Financial Performance

In 2024, Codexis's revenue was $59.35 million, a decrease of -15.39% compared to the previous year's $70.14 million. Losses were -$65.28 million, -14.38% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CDXS stock is "Buy." The 12-month stock price target is $11.0, which is an increase of 260.66% from the latest price.

Price Target

$11.0

(260.66% upside)

Analyst Consensus: Buy